Adalimumab
Brand: Humira / Exemptia / Hyrimoz
Immunomodulator
TNF-alpha inhibitor (human mAb)
Pharmacokinetics
| Half-life | 14 days |
| Clearance Route | reticuloendothelial |
| Active Metabolites | none |
| Notes | Given SC. Long half-life. Infection risk similar to infliximab. Avoid live vaccines. TB & HBV screening mandatory. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Injection-site reactions, serious infections (TB, fungal), malignancy risk (lymphoma), hepatitis B reactivation, cytopenias
Contraindications:
Active infection, untreated TB
Precautions:
Screen TB & HBV; avoid live vaccines; monitor CBC & LFTs